Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

BACKGROUND The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine was immunogenic, generally well tolerated, and effective against HPV-16 or HPV-18 infections, and associated precancerous lesions in an event-triggered interim analysis of the phase III randomised, double-blind, controlled PApilloma TRIal against Cancer In young Adults (PATRICIA). We now assess the vaccine efficacy in the final event-driven analysis. METHODS Women (15-25 years) were vaccinated at months 0, 1, and 6. Analyses were done in the according-to-protocol cohort for efficacy (ATP-E; vaccine, n=8093; control, n=8069), total vaccinated cohort (TVC, included all women receiving at least one vaccine dose, regardless of their baseline HPV status; represents the general population, including those who are sexually active; vaccine, n=9319; control, n=9325), and TVC-naive (no evidence of oncogenic HPV infection at baseline; represents women before sexual debut; vaccine, n=5822; control, n=5819). The primary endpoint was to assess vaccine efficacy against cervical intraepithelial neoplasia 2+ (CIN2+) that was associated with HPV-16 or HPV-18 in women who were seronegative at baseline, and DNA negative at baseline and month 6 for the corresponding type (ATP-E). This trial is registered with ClinicalTrials.gov, number NCT00122681. FINDINGS Mean follow-up was 34.9 months (SD 6.4) after the third dose. Vaccine efficacy against CIN2+ associated with HPV-16/18 was 92.9% (96.1% CI 79.9-98.3) in the primary analysis and 98.1% (88.4-100) in an analysis in which probable causality to HPV type was assigned in lesions infected with multiple oncogenic types (ATP-E cohort). Vaccine efficacy against CIN2+ irrespective of HPV DNA in lesions was 30.4% (16.4-42.1) in the TVC and 70.2% (54.7-80.9) in the TVC-naive. Corresponding values against CIN3+ were 33.4% (9.1-51.5) in the TVC and 87.0% (54.9-97.7) in the TVC-naive. Vaccine efficacy against CIN2+ associated with 12 non-vaccine oncogenic types was 54.0% (34.0-68.4; ATP-E). Individual cross-protection against CIN2+ associated with HPV-31, HPV-33, and HPV-45 was seen in the TVC. INTERPRETATION The HPV-16/18 AS04-adjuvanted vaccine showed high efficacy against CIN2+ associated with HPV-16/18 and non-vaccine oncogenic HPV types and substantial overall effect in cohorts that are relevant to universal mass vaccination and catch-up programmes. FUNDING GlaxoSmithKline Biologicals.

[1]  David R. Scott,et al.  The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. , 2005, Journal of the National Cancer Institute.

[2]  S. Coughlin,et al.  Burden of cervical cancer in the United States, 1998–2003 , 2008, Cancer.

[3]  M. Lehtinen,et al.  Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. , 2007, The Journal of adolescent health : official publication of the Society for Adolescent Medicine.

[4]  F. Bray,et al.  Incidence Trends of Adenocarcinoma of the Cervix in 13 European Countries , 2005, Cancer Epidemiology Biomarkers & Prevention.

[5]  Qi Jiang,et al.  Independent Data Monitoring Committees , 2010 .

[6]  W. Quint,et al.  Highly Effective Detection of Human Papillomavirus 16 and 18 DNA by a Testing Algorithm Combining Broad-Spectrum and Type-Specific PCR , 2006, Journal of Clinical Microbiology.

[7]  C. Key,et al.  The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study. , 2000, Gynecologic oncology.

[8]  Thomas Breuer,et al.  Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. , 2008, Vaccine.

[9]  C. Poole,et al.  Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[10]  C. Wheeler,et al.  Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial , 2006, The Lancet.

[11]  Henry C Kitchener,et al.  Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial , 2007, The Lancet.

[12]  B. Monk,et al.  Age Considerations When Vaccinating against Hpv , 2008 .

[13]  W. Quint,et al.  Persistence of an Incident Human Papillomavirus Infection and Timing of Cervical Lesions in Previously Unexposed Young Women , 2009, Cancer Epidemiology Biomarkers & Prevention.

[14]  Elizabeth R Unger,et al.  Prevalence of HPV infection among females in the United States. , 2007, JAMA.

[15]  L. Pinto,et al.  Correlation between direct ELISA, single epitope-based inhibition ELISA and Pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine , 2008, Human vaccines.

[16]  Daron G Ferris,et al.  Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial , 2004, The Lancet.

[17]  J. Dungan.  Effect of Human Papillomavirus 16/18 L1 Viruslike Particle Vaccine Among Young Women With Preexisting Infection: A Randomized Trial , 2008 .

[18]  F. X. Bosch,et al.  Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. , 2008, Vaccine.

[19]  E. Dasbach,et al.  The health and economic burden of genital warts in a set of private health plans in the United States. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  P. Rosenberg,et al.  Etiologic Heterogeneity for Cervical Carcinoma by Histopathologic Type, Using Comparative Age-Period-Cohort Models , 2009, Cancer Epidemiology Biomarkers & Prevention.

[21]  C. Wheeler,et al.  Human Papillomavirus Genotype Distributions: Implications for Vaccination and Cancer Screening in the United States , 2009, Journal of the National Cancer Institute.

[22]  M Arbyn,et al.  Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis , 2006, The Lancet.

[23]  A. Giuliano,et al.  Prevalence of HPV infection among men: A systematic review of the literature. , 2006, The Journal of infectious diseases.

[24]  B. Spiessens,et al.  Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: A pooled analysis of 11 clinical trials , 2009, Human vaccines.

[25]  M. Lehtinen,et al.  Enrolment of 22,000 adolescent women to cancer registry follow-up for long-term human papillomavirus vaccine efficacy: guarding against guessing , 2006, International journal of STD & AIDS.

[26]  R. Herrero.  Human papillomavirus (HPV) vaccines: limited cross-protection against additional HPV types. , 2009, The Journal of infectious diseases.

[27]  C. Wheeler,et al.  Effi cacy of a prophylactic adjuvanted bivalent L 1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women : an interim analysis of a phase III double-blind , randomised controlled trial , 2007 .

[28]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. , 2009, The Journal of infectious diseases.

[29]  S. Wacholder,et al.  CIN2 Is a Much Less Reproducible and Less Valid Diagnosis than CIN3: Results from a Histological Review of Population-Based Cervical Samples , 2007, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[30]  C. Wheeler,et al.  The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. , 2009, The Journal of infectious diseases.

[31]  W. Prendiville,et al.  Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis , 2008, BMJ : British Medical Journal.

[32]  Brigitte Colau,et al.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. , 2006, Vaccine.

[33]  D. Jenkins.  A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. , 2008, Gynecologic oncology.

[34]  N. Kiviat,et al.  Development and duration of human papillomavirus lesions, after initial infection. , 2005, The Journal of infectious diseases.